Optimizing a high‐sensitivity NanoLuc‐based bioluminescence system for in vivo evaluation of antimicrobial treatment
Focal and systemic infections are serious threats to human health. Preclinical models enable the development of new drugs and therapeutic regimens. In vivo, animal bioluminescence (BL) imaging has been used with bacterial reporter strains to evaluate antimicrobial treatment effects. However, high‐se...
Saved in:
Published in | mLife Vol. 2; no. 4; pp. 462 - 478 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Australia
John Wiley & Sons, Inc
01.12.2023
John Wiley and Sons Inc Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Focal and systemic infections are serious threats to human health. Preclinical models enable the development of new drugs and therapeutic regimens. In vivo, animal bioluminescence (BL) imaging has been used with bacterial reporter strains to evaluate antimicrobial treatment effects. However, high‐sensitivity bioluminescent systems are required because of the limited tissue penetration and low brightness of the BL signals of existing approaches. Here, we report that NanoLuc (Nluc) showed better performance than LuxCDABE in bacteria. However, the retention rate of plasmid constructs in bacteria was low. To construct stable Staphylococcus aureus reporter strains, a partner protein enolase (Eno) was identified by screening of S. aureus strain USA300 for fusion expression of Nluc‐based luciferases, including Nluc, Teluc, and Antares2. Different substrates, such as hydrofurimazine (HFZ), furimazine (FUR), and diphenylterazine (DTZ), were used to optimize a stable reporter strain/substrate pair for BL imaging. S. aureus USA300/Eno‐Antares2/HFZ produced the highest number of photons of orange‐red light in vitro and enabled sensitive BL tracking of S. aureus in vivo, with sensitivities of approximately 10 CFU from mouse skin and 750 CFU from mouse kidneys. USA300/Eno‐Antares2/HFZ was a powerful combination based on the longitudinal evaluation of the therapeutic efficacy of antibiotics. The optimized S. aureus Eno‐Antares2/HFZ pair provides a technological advancement for the in vivo evaluation of antimicrobial treatment.
Impact statement
Bioluminescence (BL) imaging with bacterial reporters has remained a powerful strategy to evaluate antibiotic treatment effects in vivo. In this study, we showed that NanoLuc (Nluc) worked effectively in bacteria, while the retention rate of plasmid in bacteria was low. A partner molecule enolase (Eno) was screened out from Staphylococcus aureus strain USA300 for stable fusion expression of Nluc‐based luciferases. We demonstrated that Nluc‐based luciferases showed superior sensitivity for BL imaging of S. aureus in vitro and in vivo. Our study may provide a model for generating other bacterial reporters for BL imaging applications. |
---|---|
Bibliography: | These authors contributed equally to this work. Edited by Wei Huang, University of Oxford, UK ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 2770-100X 2097-1699 2770-100X |
DOI: | 10.1002/mlf2.12091 |